These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Surgery. Buscail E; Alix-Panabières C; Quincy P; Cauvin T; Chauvet A; Degrandi O; Caumont C; Verdon S; Lamrissi I; Moranvillier I; Buscail C; Marty M; Laurent C; Vendrely V; Moreau-Gaudry F; Bedel A; Dabernat S; Chiche L Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31717747 [TBL] [Abstract][Full Text] [Related]
3. Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma. Loft M; Lee B; Tie J; Gibbs P J Pers Med; 2019 Jul; 9(3):. PubMed ID: 31323810 [TBL] [Abstract][Full Text] [Related]
4. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661 [TBL] [Abstract][Full Text] [Related]
5. Circulating Tumour Cells, Cell Free DNA and Tumour-Educated Platelets as Reliable Prognostic and Management Biomarkers for the Liquid Biopsy in Multiple Myeloma. Allegra A; Cancemi G; Mirabile G; Tonacci A; Musolino C; Gangemi S Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077672 [TBL] [Abstract][Full Text] [Related]
6. A Comprehensive Review of the Potential Role of Liquid Biopsy as a Diagnostic, Prognostic, and Predictive Biomarker in Pancreatic Ductal Adenocarcinoma. Stosic K; Senar OA; Tarfouss J; Bouchart C; Navez J; Van Laethem JL; Arsenijevic T Cells; 2023 Dec; 13(1):. PubMed ID: 38201207 [TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA. Lee JS; Park SS; Lee YK; Norton JA; Jeffrey SS Mol Oncol; 2019 Aug; 13(8):1623-1650. PubMed ID: 31243883 [TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594 [TBL] [Abstract][Full Text] [Related]
11. Pancreatic Cancer Diagnosis and Management: Has the Time Come to Prick the Bubble? Moutinho-Ribeiro P; Macedo G; Melo SA Front Endocrinol (Lausanne); 2018; 9():779. PubMed ID: 30671023 [TBL] [Abstract][Full Text] [Related]
12. Tumour-derived exosomes as a signature of pancreatic cancer - liquid biopsies as indicators of tumour progression. Nuzhat Z; Kinhal V; Sharma S; Rice GE; Joshi V; Salomon C Oncotarget; 2017 Mar; 8(10):17279-17291. PubMed ID: 27999198 [TBL] [Abstract][Full Text] [Related]
13. Pretherapeutic evaluation of patients with upper gastrointestinal tract cancer using endoscopic and laparoscopic ultrasonography. Mortensen MB Dan Med J; 2012 Dec; 59(12):B4568. PubMed ID: 23290296 [TBL] [Abstract][Full Text] [Related]
14. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652 [TBL] [Abstract][Full Text] [Related]
15. Pancreatic cancer: Are "liquid biopsies" ready for prime-time? Lewis AR; Valle JW; McNamara MG World J Gastroenterol; 2016 Aug; 22(32):7175-85. PubMed ID: 27621566 [TBL] [Abstract][Full Text] [Related]
16. The Role of Circulating Biomarkers in Lung Cancer. Herath S; Sadeghi Rad H; Radfar P; Ladwa R; Warkiani M; O'Byrne K; Kulasinghe A Front Oncol; 2021; 11():801269. PubMed ID: 35127511 [TBL] [Abstract][Full Text] [Related]
17. Liquid biopsy assessment of synchronous malignancies: a case report and review of the literature. Liebs S; Nonnenmacher A; Klauschen F; Keilholz U; Vecchione L ESMO Open; 2019; 4(4):e000528. PubMed ID: 31555482 [TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy: An arsenal for tumour screening and early diagnosis. Zhang Q; Zhang X; Xie P; Zhang W Cancer Treat Rev; 2024 Sep; 129():102774. PubMed ID: 38851148 [TBL] [Abstract][Full Text] [Related]
19. The Significance of Liquid Biopsy in Pancreatic Cancer. Qi ZH; Xu HX; Zhang SR; Xu JZ; Li S; Gao HL; Jin W; Wang WQ; Wu CT; Ni QX; Yu XJ; Liu L J Cancer; 2018; 9(18):3417-3426. PubMed ID: 30271504 [TBL] [Abstract][Full Text] [Related]
20. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Castillo J; Bernard V; San Lucas FA; Allenson K; Capello M; Kim DU; Gascoyne P; Mulu FC; Stephens BM; Huang J; Wang H; Momin AA; Jacamo RO; Katz M; Wolff R; Javle M; Varadhachary G; Wistuba II; Hanash S; Maitra A; Alvarez H Ann Oncol; 2018 Jan; 29(1):223-229. PubMed ID: 29045505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]